# LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Source: https://onco.cc/trials/nct04752722/  
OnCo record `nct04752722` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of EG-70 (phase 1) in bladder & urothelial cancer, run by enGene, Inc., now recruiting.

## Summary

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve is a phase 1/2 interventional study registered as NCT04752722 by enGene, Inc., with 350 participants planned, started 2021-04-22 and due to reach its primary completion in 2028-04-30. Interventions recorded: EG-70 (phase 1), EG-70 (phase 2) Master Protocol and Surfactant Bladder Pre-Rinse and EG-70 (Substudy).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04752722
- Phase: 1/2
- Setting: A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment
- Sponsor: enGene, Inc.
- Enrolled: 350

## Sources

- ClinicalTrials.gov NCT04752722: https://clinicaltrials.gov/study/NCT04752722

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)

---
JSON: https://onco.cc/api/v1/entities/nct04752722.json